Skip to main content

HIV Pre-exposure Prophylaxis and Buprenorphine at a Drug Detoxification Center During the Opioid Epidemic: Opportunities and Challenges

Abstract

Human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) and buprenorphine decrease HIV acquisition. Between November, 2016 and July, 2017, we surveyed persons (N = 200) at a drug detoxification center to assess their interest in PrEP and in buprenorphine, and to examine factors associated with such interests. Over the previous 6 months, 58% (117/200) injected drugs, 87% (173/200) used opioids, 50% (85/171) had condomless sex. Only 22% (26/117) of persons who injected drugs were aware of PrEP, yet 74% (86/116) and 72% (84/116) were interested in oral or injectable PrEP, respectively. Thirty-eight percent (47/125) of persons not receiving buprenorphine or methadone expressed interest in buprenorphine. After multivariable adjustment, Latinx ethnicity was associated with interest in PrEP (aOR 3.80; 95% CI 1.37–10.53), while male gender (aOR 2.76; 95% CI 1.21–6.34) was associated with interest in buprenorphine. Opportunities exist to implement PrEP and buprenorphine within drug detoxification centers.

Clinical trial registration NCT02869776. Clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT02869776?term=Sabrina+Assoumou&cond=HIV+HCV&rank=1.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3

References

  1. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.

    Article  Google Scholar 

  2. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349(10):949–58.

    CAS  Article  Google Scholar 

  3. USPSTF, Owens DK, Davidson KW, et al. Preexposure prophylaxis for the prevention of HIV infection: US preventive services task force recommendation statement. JAMA J Am Med Assoc. 2019;321(22):2203–13.

    Article  Google Scholar 

  4. Centers for Disease Control and Prevention: US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States—2017 update: a clinical practice guideline. March 2018. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf. Accessed on 12 June 2020.

  5. Schwartz RP, Gryczynski J, O’Grady KE, et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995–2009. Am J Public Health. 2013;103(5):917–22.

    Article  Google Scholar 

  6. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008;2008(2):CD002207.

    Google Scholar 

  7. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;2009(3):CD002209.

    PubMed Central  Google Scholar 

  8. Sullivan LE, Moore BA, Chawarski MC, et al. Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Subst Abuse Treat. 2008;35(1):87–92.

    Article  Google Scholar 

  9. Conrad C, Bradley HM, Broz D, et al. Community outbreak of HIV infection linked to injection drug use of oxymorphone-Indiana, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(16):443–4.

    PubMed  PubMed Central  Google Scholar 

  10. Alpren C, Dawson EL, John B, et al. Opioid use fueling HIV transmission in an urban setting: an outbreak of HIV infection among people who inject drugs—Massachusetts, 2015–2018. Am J Public Health. 2020;110(1):37–44.

    Article  Google Scholar 

  11. Bazzi AR, Drainoni ML, Biancarelli DL, et al. Systematic review of HIV treatment adherence research among people who inject drugs in the United States and Canada: evidence to inform pre-exposure prophylaxis (PrEP) adherence interventions. BMC Public Health. 2019;19(1):31.

    Article  Google Scholar 

  12. Knudsen HK, Abraham AJ, Roman PM. Adoption and implementation of medications in addiction treatment programs. J Addict Med. 2011;5(1):21–7.

    Article  Google Scholar 

  13. Kuo I, Olsen H, Patrick R, et al. Willingness to use HIV pre-exposure prophylaxis among community-recruited, older people who inject drugs in Washington, DC. Drug Alcohol Depend. 2016;164:8–13.

    Article  Google Scholar 

  14. Walters SM, Kral AH, Simpson KA, Wenger L, Bluthenthal RN. HIV pre-exposure prophylaxis prevention awareness, willingness, and perceived barriers among people who inject drugs in Los Angeles and San Francisco, CA, 2016–2018. Subst Use Misuse. 2020;55(14):2409–19.

    Article  Google Scholar 

  15. Biancarelli DL, Biello KB, Childs E, et al. Strategies used by people who inject drugs to avoid stigma in healthcare settings. Drug Alcohol Depend. 2019;198:80–6.

    Article  Google Scholar 

  16. Assoumou SA, Paniagua SM, Linas BP, et al. Rapid versus laboratory-based testing for HIV and hepatitis C at a drug detoxification treatment center: a randomized trial. J Infect Dis. 2020;222(Supplement_5):S376–83.

    Article  Google Scholar 

  17. Caudarella A, Dong H, Milloy MJ, Kerr T, Wood E, Hayashi K. Non-fatal overdose as a risk factor for subsequent fatal overdose among people who inject drugs. Drug Alcohol Depend. 2016;162:51–5.

    Article  Google Scholar 

  18. Snow RL, Simon RE, Jack HE, Oller D, Kehoe L, Wakeman SE. Patient experiences with a transitional, low-threshold clinic for the treatment of substance use disorder: a qualitative study of a bridge clinic. J Subst Abuse Treat. 2019;107:1–7.

    Article  Google Scholar 

  19. Springer SA, Del Rio C. Addressing the intersection of infectious disease epidemics and opioid and substance use epidemics. Infect Dis Clin N Am. 2020;34(3):xiii–xiv.

    Article  Google Scholar 

  20. Friedmann PD, Suzuki J. More beds are not the answer: transforming detoxification units into medication induction centers to address the opioid epidemic. Addict Sci Clin Pract. 2017;12(1):29.

    Article  Google Scholar 

  21. HIV Prevention Trials Network. HPTN 083 study demonstrates superiority of cabotegravir for the prevention of HIV. https://www.hptn.org/news-and-events/press-releases/hptn-083-study-demonstrates-superiority-cabotegravir-prevention-hiv. Accessed on 10 Aug 2020.

  22. Sherman SG, Schneider KE, Park JN, et al. PrEP awareness, eligibility, and interest among people who inject drugs in Baltimore, Maryland. Drug Alcohol Depend. 2019;195:148–55.

    Article  Google Scholar 

  23. Biello KB, Edeza A, Salhaney P, et al. A missing perspective: injectable pre-exposure prophylaxis for people who inject drugs. AIDS Care. 2019;31(10):1214–20.

    CAS  Article  Google Scholar 

  24. Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV epidemic: a plan for the United States. JAMA J Am Med Assoc. 2019;321(9):844–5.

    Article  Google Scholar 

  25. Barreras JL, Linnemayr SL, MacCarthy S. “We have a stronger survival mode”: exploring knowledge gaps and culturally sensitive messaging of PrEP among Latino men who have sex with men and Latina transgender women in Los Angeles, CA. AIDS Care. 2019;31(10):1221–7.

    CAS  Article  Google Scholar 

  26. Wingood GM, Dunkle K, Camp C, et al. Racial differences and correlates of potential adoption of preexposure prophylaxis: results of a national survey. J Acquir Immune Defic Syndr (1999). 2013;63(Suppl 1):S95–101.

    Article  Google Scholar 

  27. Kanny D, Jeffries WL IV, Chapin-Bardales J, et al. Racial/ethnic disparities in HIV preexposure prophylaxis among men who have sex with men—23 urban areas, 2017. MMWR Morb Mortal Wkly Rep. 2019;68(37):801–6.

    Article  Google Scholar 

  28. Hess KL, Hu X, Lansky A, Mermin J, Hall HI. Lifetime risk of a diagnosis of HIV infection in the United States. Ann Epidemiol. 2017;27(4):238–43.

    Article  Google Scholar 

  29. Alford DP, LaBelle CT, Kretsch N, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med. 2011;171(5):425–31.

    Article  Google Scholar 

  30. Godersky ME, Saxon AJ, Merrill JO, Samet JH, Simoni JM, Tsui JI. Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence. Addict Sci Clin Pract. 2019;14(1):11.

    Article  Google Scholar 

  31. Morgan JR, Schackman BR, Leff JA, Linas BP, Walley AY. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abuse Treat. 2018;85:90–6.

    Article  Google Scholar 

  32. National Library of Medicine (U.S.). (2021) A study comparing oral buprenorphine and injectable buprenorphine for the treatment of opioid use disorder (VA-BRAVE). Identifier NCT04375033. https://clinicaltrials.gov/ct2/show/NCT04375033?term=injection+buprenorphine&recrs=ab&draw=2&rank=2.

  33. Norton BL, Akiyama MJ, Zamor PJ, Litwin AH. Treatment of chronic hepatitis C in patients receiving opioid agonist therapy: a review of best practice. Infect Dis Clin N Am. 2018;32(2):347–70.

    Article  Google Scholar 

  34. Green TC, Clarke J, Brinkley-Rubinstein L, et al. Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system. JAMA Psychiatry. 2018;75(4):405–7.

    Article  Google Scholar 

  35. Fanucchi L, Springer SA, Korthuis PT. Medications for treatment of opioid use disorder among persons living with HIV. Curr HIV/AIDS Rep. 2019;16(1):1–6.

    Article  Google Scholar 

  36. Shanahan CW, Beers D, Alford DP, Brigandi E, Samet JH. A transitional opioid program to engage hospitalized drug users. J Gen Intern Med. 2010;25(8):803–8.

    Article  Google Scholar 

Download references

Acknowledgements

The authors would like to thank study participants and our research team for their contributions to this work.

Funding

This work was supported by the National Institute of Allergy and Infectious Diseases [P30AI042853 Providence/Boston Center for AIDS Research collaborative developmental grant to S.A.A]; and the National Institute of Drug Abuse [R25DA035163 pilot award to S.A.A, K23DA044085 to S.A.A, R01DA046527 to B.P.L, and P30DA040500 to B.P.L]. The content is solely the responsibility of the authors and does not necessarily represent the official views of National Institutes of Health.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sabrina A. Assoumou.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Findings were presented as a poster at the College on Problems of Drug Dependence (CPDD), San Diego, California, June 11th, 2018.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Assoumou, S.A., Paniagua, S.M., Gonzalez, P. et al. HIV Pre-exposure Prophylaxis and Buprenorphine at a Drug Detoxification Center During the Opioid Epidemic: Opportunities and Challenges. AIDS Behav 25, 2591–2598 (2021). https://doi.org/10.1007/s10461-021-03220-0

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10461-021-03220-0

Keywords

  • Pre-exposure prophylaxis
  • Persons who inject drugs
  • Human immunodeficiency virus
  • Medication for opioid use disorder
  • Drug detoxification center